Research Analysts Set Expectations for DFTX Q3 Earnings

Definium Therapeutics, Inc. (NASDAQ:DFTX) – HC Wainwright lowered their Q3 2026 earnings estimates for Definium Therapeutics in a report issued on Monday, August 10th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.53) per share for the quarter, down from their previous estimate of ($0.46). The consensus estimate for Definium Therapeutics’ current full-year earnings is ($2.65) per share. HC Wainwright also issued estimates for Definium Therapeutics’ Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($3.05) EPS, Q1 2027 earnings at ($0.49) EPS, Q2 2027 earnings at ($0.48) EPS, Q3 2027 earnings at ($0.48) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($1.71) EPS, FY2028 earnings at $0.33 EPS, FY2029 earnings at $2.99 EPS and FY2030 earnings at $5.87 EPS.

A number of other research analysts also recently commented on the company. Royal Bank Of Canada reiterated an “outperform” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Needham & Company LLC boosted their price target on shares of Definium Therapeutics from $38.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, June 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Friday, July 17th. Piper Sandler reiterated an “overweight” rating and set a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Finally, Wells Fargo & Company assumed coverage on shares of Definium Therapeutics in a research note on Monday, July 27th. They issued an “overweight” rating and a $68.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Definium Therapeutics currently has an average rating of “Buy” and a consensus target price of $55.00.

Definium Therapeutics Trading Down 9.4%

Shares of DFTX stock opened at $40.91 on Wednesday. Definium Therapeutics has a 12-month low of $8.70 and a 12-month high of $49.70. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The stock’s 50-day moving average price is $38.68 and its 200-day moving average price is $26.34. The stock has a market capitalization of $4.08 billion, a price-to-earnings ratio of -11.93 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89).

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Commodore Capital LP raised its stake in shares of Definium Therapeutics by 10.5% in the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after acquiring an additional 475,000 shares during the period. Vanguard Group Inc. boosted its stake in shares of Definium Therapeutics by 11.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock worth $23,732,000 after purchasing an additional 198,878 shares during the period. Bank of New York Mellon Corp grew its holdings in Definium Therapeutics by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock valued at $36,563,000 after purchasing an additional 24,349 shares during the last quarter. UBS Group AG grew its holdings in Definium Therapeutics by 7.3% during the 3rd quarter. UBS Group AG now owns 551,809 shares of the company’s stock valued at $6,506,000 after purchasing an additional 37,364 shares during the last quarter. Finally, Orbimed Advisors LLC purchased a new stake in Definium Therapeutics in the 3rd quarter worth about $4,337,000. Institutional investors own 27.91% of the company’s stock.

Insider Buying and Selling

In other news, insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the transaction, the insider owned 320,571 shares in the company, valued at approximately $14,435,312.13. The trade was a 3.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Matthew T. Wiley sold 2,867 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $129,101.01. Following the transaction, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. This represents a 1.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 48,096 shares of company stock valued at $2,165,763 over the last quarter. Company insiders own 2.40% of the company’s stock.

Trending Headlines about Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: HC Wainwright still forecasts Definium Therapeutics becoming profitable in FY2028, with projected earnings of $0.33 per share, followed by $2.99 in FY2029 and $5.87 in FY2030. However, all three estimates were reduced from prior forecasts, limiting the positive impact.
• Neutral Sentiment: Reported short interest remained at zero shares as of August 11, with a days-to-cover ratio of zero. This indicates no measurable short-selling pressure, although it also provides little evidence of strong bearish positioning.
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to a loss of $3.05 from a loss of $2.10, and reduced its FY2027 forecast to a loss of $1.71 from $1.22. Quarterly estimates were also cut for Q3 and Q4 2026 and all four quarters of 2027, reflecting expectations for prolonged operating losses.
• Negative Sentiment: Longer-term projections weakened as well: FY2028 EPS was reduced to $0.33 from $0.77, FY2029 to $2.99 from $3.26, and FY2030 to $5.87 from $5.98. The broad-based cuts undermine confidence in the pace of the company’s future earnings growth.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.